Vasculitis & polymyalgia rheumatica
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis
Authors' conclusion
Long-term use of mepolizumab to treat EGPA was well tolerated and resulted in sustained reductions in OCS use.
Study context
- Population
- Patients with eosinophilic granulomatosis with polyangiitis (EGPA) from MIRRA who required oral corticosteroids (OCS) ≥5 mg/day up to six months after the end of MIRRA
- Participants
- 100 patients
- Primary endpoint
- Key outcomes: AEs and use of OCS
Methodological detailsmulticentre, single-group
- Multicentre
- Single-group
Primary result
As reported in the abstract
OCS dose, median
Further findings
Patients using OCS >7.5 mg/day
Discontinued OCS · study exit
- Patients who discontinued OCS
- 28%
Safety
On-treatment adverse events (AEs)
- On-treatment AEs
- 98%
- Treatment-related AEs
- 43%
- Injection site reaction (most frequent)
- 10%
Serious AEs
- Serious AEs
- 38%
- Treatment-related serious AEs
- 6%
- No new safety signals vs MIRRA identified
Original publication
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol. Published 20 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →